patent.fyi
Applications  /  US 2026/0355120
United States Patent Application Publication

US 2026/0355120 A1

Published
Nov 12, 2026
Filed
Feb 27, 2026
Earliest date on the face
Sep 20, 2023
Classification
A61K 9/5123
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Two-unit spacing

What ifWhat if the segment indexed by a contains two repeat units?
Claim language“a is 3 or 4”

Two repeat units connect the same attachment points and shorten the segment by one or two units. The protonatable headgroup provides charge at acidic pH, and the hydrophobic tails anchor the lipid in the particle.

1.3Acyclic ether substituent

What ifWhat if the short alkyl group bears an acyclic methoxy group?
Claim language“optionally substituted heterocyclyl moiety”

A methoxy group on the end of a two-carbon alkyl segment forms a 2-methoxyethyl substituent. Its ether oxygen accepts hydrogen bonds from water, while the lipid's long hydrocarbon tails provide hydrophobic anchoring.

1.8Eight-unit segment

What ifWhat if every segment indexed by b contains eight repeat units?
Claim language“5, 6, and 7”

Eight repeat units occupy each b segment and increase its contour length. The longer segments change the spacing between their attachment points, while the lipid's hydrophobic groups still associate during particle assembly.

1.9Six-unit segment

What ifWhat if every segment indexed by c contains six repeat units?
Claim language“3, 4, and 5”

Six repeat units connect the attachment points of each c segment. The resulting increase in contour length gives the connected groups more room to shift relative to one another as the lipids pack.

1.10Single-unit connection

What ifWhat if the segment indexed by d contains one repeat unit?
Claim language“d is 2, 3, or 4”

One repeat unit maintains a covalent connection between the two attachment points and brings them closer together. The ionizable group still protonates during acidic mixing and associates with the phosphate groups of the nucleic acid.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Lipid vesicles for filter testing

A water filter test loop uses preformed asymmetric lipid vesicles containing a fluorescent dye as tracer particles. A feed reservoir supplies the suspension to a filter holder with sampling ports on both sides of the filter. Fluorescence measurements from the two ports quantify particle passage after correction for free dye measured in the feed.

Component substitution

A dye substitute for nucleic acid

Calcein replaces nucleic acid as the enclosed cargo in an asymmetric lipid vesicle used to measure leakage. A size exclusion column separates unencapsulated calcein from the loaded vesicles. A fluorescence reader measures free dye in the liquid after storage, and a detergent-treated aliquot provides the total dye reference.

Parameter or scale variation

Three temperatures for vesicle storage

A single lot of empty asymmetric lipid vesicles is divided among sealed 1 mL glass vials. Replicate vials are held at 4 °C, 20 °C, and 35 °C and sampled at 0, 24, and 72 hours. Dynamic light scattering records hydrodynamic diameter and polydispersity after each sample reaches the same measurement temperature.

Combination with existing systems

Vesicle sizing with flow fractionation

An asymmetric flow field-flow fractionation channel separates empty asymmetric lipid vesicles by hydrodynamic size. The outlet feeds a multiangle light scattering detector followed by a fraction collector. The detector records scattering intensity across the elution profile, and the collector retains selected fractions for microscopy.

Vesicle adsorption on coated sensors

A flow cell holds a silica-coated quartz crystal connected to a quartz crystal microbalance with dissipation monitoring. The cell receives buffer, a suspension of empty asymmetric lipid vesicles, and then a second buffer rinse. The instrument records resonance frequency and dissipation throughout the sequence to track adsorption and the persistence of the adsorbed layer during rinsing.

Automated or data-driven variant

Automated imaging of dye vesicles

An automated fluorescence microscope images preformed asymmetric lipid vesicles containing dye in a glass-bottom plate. Software uses an unloaded control well to estimate background and applies the same intensity threshold to every sample well. The software records fluorescent spot counts and intensities by well and flags saturated images for repeat acquisition.

Specific version of a part

Mixed saturated and unsaturated tails

R1 is a straight, saturated twelve-carbon alkyl group, and R2 is a straight eighteen-carbon alkenyl group with a cis double bond between carbons 9 and 10. The double bond introduces a bend in the longer chain.

Four-carbon ester spacer

W1 is a straight, saturated four-carbon alkylene group, and X1 is a straight, saturated twelve-carbon alkyl group. The four-carbon segment bonds to the ester carbonyl carbon, and the twelve-carbon chain bonds to the ester oxygen.

Branched saturated tail

RB is a 2-ethyldecyl group with twelve carbons and no carbon–carbon double bonds. The ethyl branch sits on the second carbon from the attachment point.

Sixteen-carbon cis tail

RC is a straight sixteen-carbon alkenyl group with one cis double bond between carbons 7 and 8, counted from the point of attachment. The double bond introduces a bend near the middle of the chain.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0170861 A1
Published
Jul 2, 2009
Filed
Mar 12, 2008
Class
A61K 31/501
Document BUS 2016/0319191 A1
Published
Nov 3, 2016
Filed
Mar 6, 2014
Class
C09K 19/322
Claim 1
Document A
Document B
1.1a is 3 or 4
1.2each of R1, R2, R3, and R4 is independently selected from: (i) optionally substituted C5-C30 alkyl, and optionally substituted C5-C30 alkenyl
R4 is alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkenyl-O-alkyl, alkoxyalkenyl, alkenyl-O-alkenyl, alkynyl-O-alkyl, hydroxyalkyl, hydroxyalkenyl, alkyl-S-alkyl, alkenyl-S-alkyl, alkyl-S-alkenyl, alkenyl-S-alkenyl, alkyl-SO-alkyl, alkenyl-SO-alkyl, alkyl-SO-alkenyl, alkenyl-SO-alkenyl, alkyl-SO2-alkyl, alkenyl-SO2-alkyl, alkyl-SO2-alkenyl, alkenyl-SO2-alkenyl, alkyl-NR9-alkyl, alkenyl-NR9-alkyl, alkyl-NR9-alkenyl, alkenyl-NR9-alkenyl, alkyl-CO2-alkyl, alkenyl-CO
A · US 2009/0170861 A1 · claim 1
In the general formula (I) above, R11 represents an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or an alkenyloxy group having 3 to 8 carbon atoms, especially preferably represents a linear alkyl group having 1 to 5 carbon atoms, a linear alkoxy group having 1 to 5 carbon atoms, or a linear alkenyl group having 2 to 5 carbon atoms. —CH2— or two or more —CH2—, which are not adjacent to each oth
B · US 2016/0319191 A1 · ¶ 66
1.3(ii) optionally substituted C1-5 alkyl which is substituted with an optionally substituted heterocyclyl moiety
R3 is a moiety selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cyclenyl, cyclenylalkyl, cyclenylalkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclenyl, heterocyclenylalkyl, heterocyclenylalkenyl, arylalkoxylalkyl, arylalkoxylalkenyl, cycloalkoxylalkyl, cycloalkoxylalkenyl, cycloalkenoxylalkyl, and cycloalkenyoxylalkenyl, wh
A · US 2009/0170861 A1 · claim 1
1.4(iii) wherein each RA is independently selected from optionally substituted C3-C28 alkyl, optionally substituted C3-C28 alkenyl, and —W1—C(O)—O—X1
R4 is alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkenyl-O-alkyl, alkoxyalkenyl, alkenyl-O-alkenyl, alkynyl-O-alkyl, hydroxyalkyl, hydroxyalkenyl, alkyl-S-alkyl, alkenyl-S-alkyl, alkyl-S-alkenyl, alkenyl-S-alkenyl, alkyl-SO-alkyl, alkenyl-SO-alkyl, alkyl-SO-alkenyl, alkenyl-SO-alkenyl, alkyl-SO2-alkyl, alkenyl-SO2-alkyl, alkyl-SO2-alkenyl, alkenyl-SO2-alkenyl, alkyl-NR9-alkyl, alkenyl-NR9-alkyl, alkyl-NR9-alkenyl, alkenyl-NR9-alkenyl, alkyl-CO2-alkyl, alkenyl-CO
A · US 2009/0170861 A1 · claim 1
1.5wherein each W1 is independently selected from optionally substituted C3-C5 alkylene and optionally substituted C3-C5 alkenylene, and each X1 is independently selected from optionally substituted C5-C30 alkyl and optionally substituted C5-C30 alkenyl
R4 is alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkenyl-O-alkyl, alkoxyalkenyl, alkenyl-O-alkenyl, alkynyl-O-alkyl, hydroxyalkyl, hydroxyalkenyl, alkyl-S-alkyl, alkenyl-S-alkyl, alkyl-S-alkenyl, alkenyl-S-alkenyl, alkyl-SO-alkyl, alkenyl-SO-alkyl, alkyl-SO-alkenyl, alkenyl-SO-alkenyl, alkyl-SO2-alkyl, alkenyl-SO2-alkyl, alkyl-SO2-alkenyl, alkenyl-SO2-alkenyl, alkyl-NR9-alkyl, alkenyl-NR9-alkyl, alkyl-NR9-alkenyl, alkenyl-NR9-alkenyl, alkyl-CO2-alkyl, alkenyl-CO
A · US 2009/0170861 A1 · claim 1
1.6(iv) wherein each RB is independently selected from optionally substituted C5-C30 alkyl, optionally substituted C5-C30 alkenyl
1.7(v) wherein each RC is independently selected from optionally substituted C5-C30 alkyl and optionally substituted C5-C30 alkenyl
1.8each b is independently selected from 5, 6, and 7
1.9each c is independently selected from 3, 4, and 5
1.10d is 2, 3, or 4
1.11wherein: R1 and R2 are not identical to one another and/or R3 and R4 are not identical to one another
1.12wherein: at least one of R1, R2, R3, and R4, is independently selected from option (iv) or option (v)

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention relates to novel compounds, which are useful as glucan synthase inhibitors, pharmaceutical compositions containing the compounds, and methods of treating or preventing fungal infections.
A · US 2009/0170861 A1 · ¶ 2
These enzymes are unique to fungi and therefore provide highly selective antifungal targets.
A · US 2009/0170861 A1 · ¶ 3
The present indention relates to a nematic liquid crystal composition of which a dielectric anisotropy (Δε) is a negative value, and which is useful as a liquid crystal display material, and a liquid crystal display element using the same.
B · US 2016/0319191 A1 · ¶ 1
However, the liquid crystal composition has not achieved a satisfactorily low viscosity satisfying the liquid crystal composition required to have high-speed response for liquid crystal television or the like.
B · US 2016/0319191 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355120 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355120/, SHA-256 dcbddc5a567d661d9273b4195f5e32bbc7a7bdad80ef896c027b0a18b45e90ad
First published
Permanent addresshttps://patent.fyi/US20260355120/
Content fingerprint (SHA-256)dcbddc5a567d661d9273b4195f5e32bbc7a7bdad80ef896c027b0a18b45e90ad
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi